

NIH Public Access

Author Manuscript

J Neuroimmunol. Author manuscript; available in PMC 2009 June 25.

Published in final edited form as:

J Neuroimmunol. 2009 January 3; 206(1-2): 14–21. doi:10.1016/j.jneuroim.2008.10.003.

Expression and regulation of antiviral protein APOBEC3G in

human neuronal cells✩

Yan-Jian Wanga, **Xu Wang**a, **Hui Zhang**c, **Lin Zhou**a, **Shi Liu**a, **Dennis L. Kolson**b, **Li Song**a, Li Ye^a, and Wen-Zhe Ho^{a,}

a*Division of Allergy & Immunology, Joseph Stokes, Jr. Research Institute at The Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA*

b*Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA*

c*Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA*

Abstract

Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) has recently been identified as a potent antiviral protein. Here, we examined the expression and regulation of APOBEC3G in human brain tissues and the cells of central nervous system (CNS). Similar to the immune cells, human brain tissue and the CNS cells expressed APOBEC3G at both mRNA and protein levels. The expression of APOBEC3G could be up-regulated in human neuronal cells (NT2- N) and astrocytes (U87-MG) by interferons (IFN-α, β and γ), interleukin-1 (IL-1), and tumor necrosis factor. Other cytokines (IL-4, IL-6 and transforming growth factor beta1) and CC-chemokines (CCL3, 4 and 5), however, had little impact on the expression of APOBEC3G. In addition, pseudotyped HIV-1 infection and cytokine/chemokine-enriched supernatants from lipopolysaccharide- stimulated macrophage cultures induced APOBEC3G expression in NT2-N cells. APOBEC3G expressed in the neuronal cells and astrocytes was biologically functional, as the suppression of APOBEC3G expression by the specific siRNA led to increase of pseudotyped HIV-1 replication in these cells. These findings provide direct and compelling evidence that there is intracellular expression and regulation of functional APOBEC3G in the neuronal cells, which may be one of innate defense mechanisms involved in the neuronal protection in the CNS.

Keywords

APOBEC3G; Cytokine; Interferon; Astrocytes; Neuron

1. Introduction

APOBEC3G, a member of the apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC) family of proteins homologous cytidine deaminase domains (Jarmuz et al.,

 $\hat{\mathcal{R}}$ This work was supported by the National Institutes of Health grants (DA012815 and DA022177 to W.Z.H.).

^{© 2008} Published by Elsevier B.V.

^{*}Corresponding author. Division of Allergy & Immunology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, 34th Street & Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA. Tel.: +1 215 590 4462; fax: +1 215 590 2025. *E-mail address:* E-mail: ho@email.chop.edu (W.-Z. Ho).

2002), has been identified as a host factor involved in cellular defense mechanism against retroviruses (Harris et al., 2003; Mangeat et al., 2003; Sheehy et al., 2002). APOBEC3G can either edit the newly synthesized viralDNA or inhibit another site(s) of the viral life cycle (Mangeat et al., 2003; Mariani et al., 2003; Turelli and Trono, 2005; Zhang et al., 2003). Recently, inhibition of human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus, equine infectious anemia virus, murine leukemia virus and hepatitis B virus by APOBEC3G has been reported (Mangeat et al., 2003; Navarro and Landau, 2004; Noguchi et al., 2005; Rosler et al., 2005).

Although APOBEC3G resides in HIV-1 permissive cells, such as CD4⁺ T cells and monocytederived macrophages (Chiu et al., 2005), expression of APOBEC3G has also been identified in other human organs, such as lungs, testes, ovaries, liver and kidney (Chen et al., 2006; Jin et al., 2005; Komohara et al., 2007, 2006; Turelli and Trono, 2005). In addition, APOBEC3G could be induced by interferons (IFNs) in human lymphocytes, macrophage, liver and kidney cells (Bonvin et al., 2006; Chen et al., 2006; Komohara et al., 2007, 2006; Peng et al., 2006; Tanaka et al., 2006). Both type I and type II IFNs play a critical role in the host innate immunity against viral infections. IFN- α is a potent inhibitor of HIV-1 infection of CCR5⁺ CD4⁺ human macrophages (Baca-Regen et al.,1994; Meylan et al.,1993). IFN-α is also a potent inducer of APOBEC3G, which overrides HIV-1 vif-mediated neutralization of APOBEC3G protein that pose a threat to efficient HIV-1 replication in macrophages (Peng et al., 2006). Although it has been demonstrated that APOBEC3G could be induced by type I IFNs in human lymphocytes, macrophage, liver and kidney (Bonvin et al., 2006; Chen et al., 2006; Komohara et al., 2007, 2006; Peng et al., 2006; Tanaka et al., 2006), there is limited information about the expression and regulation of APOBEC3G in human central nervous system (CNS), an important target for viral infections, including HIV-1. Therefore, we examined whether the CNS cells express functional APOBEC3G, and whether IFNs (alpha, beta and gamma) and other cytokines/ chemokines modulate the expression of APOBEC3G in the human neuronal cells.

2. Materials and methods

2.1. Primary cells

Human brain tissues used were obtained from the National Neurological Research Specimen Bank (Los Angeles, CA). Neural precursor cell (NPC)-derived human neuronal cells were kindly obtained from Dr. Hu, Shuxian (The Center for Infectious Diseases and Microbiology Translational Research, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota). NPC cultures were prepared from the telencephalon of 8- to 10 week-old human fetal brain using previously described methods (Hu et al., 2006, 2002; Ni et al., 2004; Uchida et al., 2000). Peripheral blood samples were obtained from healthy adult donors. The Institutional Review Board of the Children's Hospital of Philadelphia approved this investigation. Informed consent was obtained from the subjects. Peripheral blood lymphocytes (PBL) and monocytes were processed as described previously (Hassan et al., 1986). Freshly isolated monocytes were plated in 48-well culture plates at a density of 0.5 \times 10⁶ cells per well in DMEM containing 10% fetal bovine serum (FBS) (Invitrogen). Macrophages referred to 7-day-cultured monocytes. Monocyte/macrophage viability was monitored by trypan blue exclusion and maintenance of cell adherence. In all cases, limulus amebocyte lysate assay demonstrated that media and reagents were endotoxin-free.

2.2. Cell lines

Human neuronal cells (NT2-N) were derived from differentiated Ntera-2clD/1 (NT2) cells as described previously (Andrews, 1984). In brief, NT2 cells were plated at a density of 2.3 \times 10⁶ per T75 flask and fed twice weekly with DMEM containing high glucose (Gibco, Grand Island, NY, USA) and 10% FBS (Hyclone, Iogan, UT, USA) with 100 U/ml penicillin plus

100 µg/ml streptomycin (Gibco) and 10−⁵ M retinoic acid (RA) (Sigma-Aldrich, St. Louis, MO, USA) for 5 weeks. The cells were then divided (1:4) and grown for an additional 48 h in identical medium without RA. Neuronal cells growing above a monolayer of non-neuronal cells were dislodged with trypsin and plated at a density of 0.5×10^6 cells per well in a 24well plate for this study. NT2-N neurons have morphologic features similar to primary human neurons, and have processes that differentiate into axons and dendrites (Andrews, 1984). NT2- N neurons also express cytoskeletal proteins, secretory markers, and surface markers, which are characteristic of neurons. They also express functional neuropeptides (Guillemain et al., 2000) and functional *N*-methyl-_p-aspartate (NMDA) and non-NMDA glutamate receptors (Younkin et al., 1993). Undifferentiated human NT2 cells grafted into mouse brain differentiated into neuronal and glial cells (Ferrari et al., 2000).

The neuroblastoma cell lines (CHP212 and SY5Y) were purchased from American Type Tissue Culture (ATCC; Manassas, VA). CHP212 cells were cultured in Eagle's MEM-Ham F12 (1:1) medium containing 10% FCS, 0.1 mM non-essential amino acid and 1.0 mM sodium pyruvate. SY5Y cells were propagated in DMEM with high glucose containing 10% FBS. Human astroglioma cells (U87-MG) and human B lymphoblasts (IM9) were obtained from ATCC (Rockville, MD). U87-MG and IM9 cells were maintained in DMEM with 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% FBS. The human NK cell line (YTS) was a subclone of the YT lymphoid cell line, derived from a patient with NK cell leukemia and interleukin-2-independent (Cohen et al., 1999). YTS cells were cultured in Iscover's modified Dulbecco's medium (IMDM) supplemented with 10% FCS and 2 mM $_L$ -glutamine.

2.3. Reagents

Recombinant human interferon (IFN-α, IFN-β, and IFN-γ), interleukin-1beta (IL-1β), IL-4, IL-6, Transforming Growth Factor Beta1 (TGF-β1), CC chemokine ligand 3 (CCL3), CCL4, CCL5 and tumor necrosis factor-α (TNF-α) were purchased from R&D Systems (Minneapolis, MN, USA). Rabbit polyclonal anti-APOBEC3G antibody was purchased from Immuno Dilagnostics, Inc. (Woburn, MA, USA). Lipopolysaccharide (LPS) was purchased from Sigma (St Louis, MO, USA).

2.4. Treatment of NT2-N or U87-MG cells with cytokines or cytokine-enriched supernatants

NT2-N or U87-MG cells were cultured in the presence or absence of each of the cytokines (IFN-α, IFN-β, IFN-γ, TNF-α, IL-1β, IL-4, IL-6, TGF-β1, CCL3, CCL4 and CCL5). The concentrations of each cytokine used and different time points post-treatment are indicated in the legends for Fig. 3, and Fig.4. We also cultured NT2-N cells in media conditioned with supernatant from macrophage cultures $(0.5 \times 10^6 \text{ cells/well})$ with or without LPS (1 ng/ml) stimulation for 12 h.

2.5. Short interfering RNA transfection and pseudotyped HIV-1 infection of NT2-N neuron and U87-MG astrocytes

APOBEC3G-specific and control siRNAs were chemically synthesized by Dharmacon (Lafayett, Co). NT2-N and U87-MG cells were transfected with 100 nM APOBEC3G-specific siRNA or control siRNA using the transfection reagent (DharmaFect 3, Dharmacon, Lafayett, Co). Twenty-four hours after transfection, half of the cells were collected for APOBEC3G mRNA expression by the realtime RT-PCR. Another half of the cells were infected with MLVenv-pseudotyped HIV-1 (20 ng of p24/ml) for 16 h. The preparation of MLV-env-pseudotyped HIV-1 was described previously (Wang et al., 2002, 2006). The cells were then lysed in 100 µl of 1× Reporter Lysis Buffer (Promega Corp., Madison, WI) 72 h postinfection. Lysate (50 µl) was mixed with 100 µl of luciferase substrate (Promega Corp., Madison, WI) and luciferase activity was determined in a TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA).

2.6. Real time reverse-transcription-polymerase chain reaction (RT-PCR)

Real time RT-PCR was described previously (Guo et al., 2003). Briefly, total cellular RNA was extracted from the cells (10^6) and brain tissues using Tri-Reagent (Molecular Research Center, Cincinnati, OH). Total cellular RNA (1 µg) was subjected to reverse transcription using the reverse transcription system from Promega Corporation (Madison, WI). The real-time RT-PCR for mRNA was performed with the Brilliant SYBR Green QPCP Master Mix (Bio-Rad Laboratories, Hercules, CA). The specific oligonucleotide primers used were as follows: APOBEC3G: 5′-TCAGAGGACGGCATGAGACTTAC-3′ (sense) and 5′-

AGCAGGACCCAGGTGTCATTG-3′ (anti-sense); GAPDH (the house keeping gene): 5′- GGTGGTCTCCTCTGACTTCAACA-3′ (sense) and 5′-

GTTGCTGTAGCCAAATTCGTTGT-3′ (anti-sense). The oligonucleotide primers were synthesized by Integrated DNA Technologies Inc. (Coralville, IA). After PCR amplification, some samples were separated by 3% ultra pure agarose gel electrophoresis (Gibco-Grand Island, NY).

2.7. Western blot analysis

Total cell lysates from NT2-N cells were prepared using the lysis buffer consisted of 10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM sodium-orthovanadate, 20 µM4-(2 aminoethyl)-benzenesulfonyl fluoride, 0.2% Nonidet P-40, 5 µg/ml leupeptin, phosphatase inhibitor cocktail and protease inhibitor cocktail (Sigma). Protein concentrations were determined by DC protein assay kit (Bio-Rad, Hercules, CA). Proteins were resuspended in NuPAGE LDS Sample Buffer (NOVEX), heated for 5 min at 95 °C and then equivalent amounts of protein $(50 \mu g)$ for each sample were separated in a 10% Bis-Tris Gel in a NuPAGE Running Buffer with 0.25% Running Buffer Antioxidant for 50 min at 200 V. Proteins were transferred to the nitrocellulose membranes (Bio-Rad) in NuPAGE Transfer Buffer at 100 V for 1 h. The membranes were blocked with 5% fat-free milk in $1 \times PBS$ for 1 h and incubated with appropriate optimal diluted antibodies for actin (1:3000) for 1 h at room temperature or with rabbit polyclonal antibodies to APOBEC3G (1:1000) overnight at 4 \degree C in the blocking solution. After washing 3 times for 15 min each time with PBST (0.05% Tween 20 in PBS), the membrane was incubated with appropriate HRP-conjugated goat anti-rabbit (1:10,000) IgG antibodies in blocking solution for 1 h at room temperature and washed 3 times as described above. The bound antibodies were developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) according to the manufacturer's instruction and exposed to basic Autorad film. Pre-stained molecular markers (Bio-Rad) were used to determine molecular weight of immunoreactive bands.

2.8. Data analysis

Where appropriate, data were expressed as mean $\pm SD$. For comparison of the mean of the two groups, statistical significance was measured by Student's *t* test. Calculations were performed with Stata Statistical Software (StataCorp., College Station, TX). Statistical significance was defined as $p < 0.05$.

3. Results

3.1. APOBEC3G expression in human CNS cells and immune cells

We first examined whether human CNS cells express APOBEC3G mRNA. As shown in Fig. 1, APOBEC3G mRNA was detected in the neuronal cells, including NT2-N, SY5Y, CHP212 and U87-MG cells. Human brain tissues (Cingulate cortex and Cerebellum) also had detectable levels of APOBEC3G mRNA (Fig. 1A). The levels of APOBEC3G mRNA in the CNS cells were comparable with those in the immune cells (Fig.1A). In order to determine that human neuronal cells also express APOBEC3G protein, we performed Western blot using both NT2-

N cells and NPC-derived primary human neurons. Similar to peripheral blood lymphocytes (PBL), both NT2-N cells and primary human neurons expressed APOBEC3G protein, although the expression of APOBEC3G in primary human neurons was lower than NT2-N cells (Fig. 1B). Since undifferentiated NT2 cells, grafted into mouse brain, differentiated into neuronal cells and glial cells (Younkin et al., 1993), we also examined whether the cell differentiation affects APOBEC3G expression in NT2-N cells. Compared with undifferentiated NT2 cells, NT2-N cells (5 weeks after RA stimulation) expressed significantly higher levels of APOBEC3G at both mRNA $(> 25$ fold) and protein $(> 4$ fold) levels (Fig. 2).

3.2. Regulation of APOBEC3G expression in NT2-N by cytokines/chemokines

In the second set of experiments, we tested the hypothesis that cytokines/chemokines may have the ability to modulate APOBEC3G expression in NT2-N cells. We first examined the impact of type I/II IFNs on APOBEC3G expression in the neuronal cells. Type I IFN-α or IFN-β, when added to NT2-N or U87-MG cell cultures, induced APOBEC3G mRNA expression in a time and dose dependent fashion (Fig. 3). Similar to type I IFNs, IFN-γ also induced the expression of APOBEC3G in NT2-N cells (Fig. 4A). Among other cytokines tested, TNF- α and IL-1β also stimulated APOBEC3G mRNA expression (Fig. 4A, B and C),while IL-4, IL-6 and TGF-β1 had little effects on APOBEC3G mRNA expression (Fig. 4D, E and F). In addition, APOBEC3G expression in NT2-N cells was not affected by CC-chemokines (CCL3, CCL4 and CCL5) (data not shown).

3.3. LPS-activated macrophages produce cytokines/chemokines that induce APOBEC3G

It has been indicated that high levels of circulating LPS (a consequence of microbial translocation from a leaky gut) in AIDS parents increase monocyte activation and trafficking into the CNS, resulting in excessive production of inflammatory cytokines. This process has been suggested as a cause of HIV-associated dementia (HAD). Thus, we examined whether cytokines/chemokines produced by LPS-activated macrophages affect APOBEC3G expression in NT2-N cells. As shown in Fig. 5, NT2-N cells treated with supernatants from LPS-stimulated macrophage cultures produced significantly higher levels of APOBEC3G in NT2-N cells than those of unstimulated macrophage cultures. However, LPS, when directly added to NT2-N cell cultures conditioned with or without unstimulated macrophage cultures, had no effect on the expression of APOBEC3G.

3.4. Pseudotyped HIV-1 infection induces APOBEC3G expression and the suppression of APOBEC3G enhances HIV-1 replication

We also examined whether HIV-1 infection could induce APOBEC3G expression in NT2-N and U87-MG cells. When these cells exposed to supernatant from HIV-1 infected macrophage cultures, there was little change of the levels of APOBEC3G (data not shown). We then investigated whether MLV-env-pseudotyped HIV-1 infection could alter the expression of APOBEC3G in NT2-N and U87-MG cells. As shown in Fig. 6, there was graduated increase of APOBEC3G mRNA during the course of infection in both NT2-N cells and U87-MG cells. In order to determine APOBEC3G produced by NT2-N neuron or U87-MG astrocytes is biologically functional, we examined whether APOBEC3G has the antiHIV-1 activity. As shown in Fig. 7A, transfection of specific siRNA against APOBEC3G into NT2-N or U87- MG cells resulted in reduced expression of APOBEC3G mRNA, while negative control siRNA did not alter APOBEC3G expression. This decrease of endogenous APOBEC3G expression was correlated with the increase of MLV-env-pseudotyped HIV-1 replication in NT2-N or U87-MG cells 72 h postinfection (Fig. 7B).

4. Discussion

APOBEC3G has recently been identified as an antiviral protein that can suppress HIV-1, hepatitis B virus, murine leukemia virus, simian immunodeficiency virus and equine infectious anemia virus (Mangeat et al., 2003; Navarro and Landau, 2004; Noguchi et al., 2005; Rosler et al., 2005). These new findings prompted us to examine whether human neuronal cells express functional APOBEC3G and whether its expression is regulated by cytokines/chemokines. We demonstrated that both primary brain tissue and human neuronal cells expressed APOBEC3G at both mRNA and protein levels (Fig.1). We also demonstrated that human astroglioma cells (U87-MG) expressed APOBEC3G. These findings support the recent report that human primary neuronal cells and astrocytes expressed APOBEC3G (Argyris et al., 2007). More importantly, we demonstrated that APOBEC3G produced by NT2-N and U87-MG cells had antiviral activity, as evidenced by the observation that the cells transfected with the siRNA against APOBEC3G had higher levels of pesudotyped HIV-1 replication than untransfected or control siRNA-transfected cells (Fig. 7). This finding suggests that human neuronal cells and astrocytes produce functional APOBEC3G. Our further experiments confirmed that APOBEC3G in these cells is involved in the innate immune response to viral infection, as we showed that pseudotyped HIV-1 infection could induce APOBEC3G expression (Fig. 6). We next examined the hypothesis that cytokines/chemokines have the ability to modulate APOBEC3G expression in the neuronal cells. This speculation is based on the observations that human neuronal cells express multiple cytokine receptors (Coughlan et al., 2000; Hopkins and Rothwell,1995; Klein et al., 2000; Mehler and Kessler, 1997; Rothwell et al., 1996). In addition, several studies have demonstrated that both glial and neuronal cells express multiple functional chemokine receptors and chemokines in the CNS (Coughlan et al., 2000; Guo et al., 2003). It is well known now that cytokines and chemokines interacting with specific receptors on the neuronal cells are involved in neuroimmunoregulation.

Our initial studies focused on IFNs, as these cytokines have been demonstrated to have the ability to induce APOBEC3G expression in different cell systems. Our data that IFN-α potently up-regulated the expression of APOBEC3G in NT2-N agrees with the studies by others (Argyris et al., 2007; Bonvin et al., 2006; Chen et al., 2006; Komohara et al., 2007, 2006; Peng et al., 2006; Tanaka et al., 2006), showing that IFN-α induces APOBEC3G expression in other type of cells, including various primary cells (hepatocytes, macrophage, CD4+ T cells, plasmacytoid dendritic cells, kidney cells and brain microvascular endothelial cells) and cell lines (Huh7, HepG2 and 293T cells). In addition to IFN-α, IFN-β also enhanced APOBEC3G expression in the both neuronal cells and astrocytes (Fig. 3). This finding is highly significant since many viruses induce IFN-β prior to IFN-α expression through toll-like receptor (TLR) pathway. Similar to type I IFNs, type II IFN (IFN-γ) also induced the expression of APOBEC3G in the neuronal cells (Fig. 4A). Furthermore, several inflammatory cytokines (TNF- α and IL-1 β) also up-regulated APOBEC3G expression in the neuronal cells (Fig. 4B, C). This cytokine-mediated up-regulation of APOBEC3G expression in the neuronal cells is specific, as other cytokines (IL-4, IL-6 and TGF-β1) (Fig. 4D, E and F) and CC-chemokines (data not shown) had little or no effects on APOBEC3G expression in human neuronal cells.

In addition to our attempt to examine the effect of individual cytokine/chemokine on APOBEC3G expression, we also determined the impact of mixture of multi-cytokines/ chemokines on the expression of APOBEC3G in the neuronal cells. In order to mimic *in vivo* microenvironment where macrophages/microglia in the CNS release multiple cytokines/ chemokines that affect neuronal functions, we examined whether supernatants from macrophage cultures have impact on APOBEC3G expression in NT2-N cells. We were particularly interested in monocytes/macrophages, as these cells produce cytokines/ chemokines that act not only in a paracrine-like fashion in the microenvironment to stimulate immune responses, but also in an endocrine-like fashion on distant organs that participate in

inflammatory responses. More importantly, monocytes/macrophages have been shown to play a key role in HIV-mediated neuronal impairment in the CNS. We showed that the expression of APOBEC3G in NT2-N cells was greatly enhanced by supernatants from macrophage cultures stimulated with LPS, a well-known activator of monocytes/macrophages (Ding et al., 2001; Guo et al., 2003; Herbein et al.,1995; Lai et al., 2001; Monari et al., 2005). This activated macrophage-medicated induction of APOBEC3G is not due to the direct effect of LPS, since LPS alone (directly added toNT2-Ncultures) had no effect on APOBEC3G expression. This finding is highly significant and clinically relevant, as LPS has recently been identified as a cause of systemic immune activation in chronic HIV-1 infection (Ancuta et al., 2008; Douek, 2007). In addition, LPS induces monocyte activation, monocyte trafficking across the bloodbrain barrier (BBB), leading to the production of inflammatory cytokines in the CNS. It is known that the production of multiple cytokines/chemokines by LPS-activated macrophage/ microglia contributes to the disruption of neuronal homeostasis and development of severe neurological abnormalities, including HIV-associated dementia.

Taken together, the present study provides direct and compelling experimental evidence that there is intracellular expression and regulation of functional APOBEC3G in human neuronal cells and astrocytes, which might have a crucial role in glial and neuronal cell-mediated innate defense against viral infections in the CNS. While the mechanisms underlying the regulation of APOBEC3G and biological functions of APOBEC3G in human neuronal cells remain to be determined, the induction of functional APOBEC3G expression by both type I and type II IFNs suggests the possibility that APOBEC3G is involved in neuronal cell-mediated innate protection in the CNS. Further studies are necessary in order to determine the molecular mechanisms by which APOBEC3G is regulated by cytokines and other cellular factors in the CNS. In addition, it is of a great interest to determine whether APOBEC3G has other not yet known biological functions in the CNS.

Abbreviation

APOBEC3G, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G BDNF, brain-derived neurotrophic factor BMVECs, brain microvascular endothelial cells CCL3, CC chemokine ligand 3 CCL4, CC chemokine ligand 4 CCL5, CC chemokine ligand 5 CNS, central neurons system DMEM, Dulbecco's modified Eagle's medium DSU, densitometry scanning unit FBS, fetal calf serum hEGF, human epidermal growth factor hFGFb, human fibroblast growth factor-basic HIV-1, human immunodeficiency virus type 1 IFN-α, interferon alpha IFN-β, interferon beta IFN-γ, interferon gamma IL-1β, interleukin-1 beta IL-4, interleukin-4 IL-6, interleukin-6 IMDM, Iscover's modified Dulbecco's medium LPS, lipopolysaccharide NMDA, *N*-methyl-_D-aspartate NPC, neural precursor cell PBL, peripheral blood lymphocytes

RA, retinoic acid TGF-β1, transforming growth factor beta1 TNF-α, tumor necrosis factor alpha

Acknowledgements

We thank Drs. Shuxian Hu and Phillip K. Peterson (University of Minnesota Medical School, Minneapolis, MN, USA) for providing primary human neurons.

References

- Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 2008;3:e2516. [PubMed: 18575590]
- Andrews PW. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev. Biol 1984;103:285–293. [PubMed: 6144603]
- Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M, Zhang H. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology 2007;367:440–451. [PubMed: 17631933]
- Baca-Regen L, Heinzinger N, Stevenson M, Gendelman HE. Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J. Virol 1994;68:7559–7565. [PubMed: 7933143]
- Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, Greeve J. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006;43:1364–1374. [PubMed: 16729314]
- Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol 2006;80:7645–7657. [PubMed: 16840343]
- Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005;435:108–114. [PubMed: 15829920]
- Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661–671. [PubMed: 10403641]
- Coughlan CM, McManus CM, Sharron M, Gao Z, Murphy D, Jaffer S, Choe W, Chen W, Hesselgesser J, Gaylord H, Kalyuzhny A, Lee VM, Wolf B, Doms RW, Kolson DL. Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 2000;97:591–600. [PubMed: 10828541]
- Ding XZ, Fernandez-Prada CM, Bhattacharjee AK, Hoover DL. Over-expression of hsp-70 inhibits bacterial lipopolysaccharide-induced production of cytokines in human monocyte-derived macrophages. Cytokine 2001;16:210–219. [PubMed: 11884024]
- Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top. HIV Med 2007;15:114–117. [PubMed: 17720995]
- Ferrari A, Ehler E, Nitsch RM, Gotz J. Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types. FEBS Lett 2000;486:121–125. [PubMed: 11113451]
- Guillemain I, Alonso G, Patey G, Privat A, Chaudieu I. Human NT2 neurons express a large variety of neurotransmission phenotypes in vitro. J. Comp. Neurol 2000;422:380–395. [PubMed: 10861514]
- Guo CJ, Douglas SD, Lai JP, Pleasure DE, Li Y, Williams M, Bannerman P, Song L, Ho WZ. Interleukin-1beta stimulates macrophage inflammatory protein-1alpha and -1beta expression in human neuronal cells (NT2-N). J. Neurochem 2003;84:997–1005. [PubMed: 12603824]
- Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. DNA deamination mediates innate immunity to retroviral infection. Cell 2003;113:803–809. [PubMed: 12809610]

- Hassan NF, Campbell DE, Douglas SD. Purification of human monocytes on gelatin-coated surfaces. J. Immunol. Methods 1986;95:273–276. [PubMed: 3794346]
- Herbein G, Doyle AG, Montaner LJ, Gordon S. Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1 beta. Clin. Exp. Immunol 1995;102:430–437. [PubMed: 7586702]
- Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci 1995;18:83–88. [PubMed: 7537419]
- Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine induces apoptosis of human microglia and neurons. Neuropharmacology 2002;42:829–836. [PubMed: 12015209]
- Hu S, Cheeran MC, Sheng WS, Ni HT, Lokensgard JR, Peterson PK. Cocaine alters proliferation, migration, and differentiation of human fetal brain-derived neural precursor cells. J. Pharmacol. Exp. Ther 2006;318:1280–1286. [PubMed: 16766721]
- Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002;79:285–296. [PubMed: 11863358]
- Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol 2005;79:11513–11516. [PubMed: 16103203]
- Klein BD, White HS, Callahan KS. Cytokine and intracellular signaling regulation of tissue factor expression in astrocytes. Neurochem. Int 2000;36:441–449. [PubMed: 10733012]
- Komohara Y, Yano H, Shichijo S, Shimotohno K, Itoh K, Yamada A. High expression of APOBEC3G in patients infected with hepatitis C virus. J. Mol. Histol 2006;37:327–332. [PubMed: 17036163]
- Komohara Y, Suekane S, Noguchi M, Matsuoka K, Yamada A, Itoh K. Expression of APOBEC3G in kidney cells. Tissue Antigens 2007;69:95–98. [PubMed: 17212712]
- Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc. Natl. Acad. Sci. U. S. A 2001;98:3970– 3975. [PubMed: 11274418]
- Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003;424:99–103. [PubMed: 12808466]
- Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003;114:21–31. [PubMed: 12859895]
- Mehler MF, Kessler JA. Hematolymphopoietic and inflammatory cytokines in neural development. Trends Neurosci 1997;20:357–365. [PubMed: 9246730]
- Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS. Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages. Virology 1993;193:138–148. [PubMed: 7679856]
- Monari C, Bistoni F, Casadevall A, Pericolini E, Pietrella D, Kozel TR, Vecchiarelli A. Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages. J. Infect. Dis 2005;191:127–137. [PubMed: 15593014]
- Navarro F, Landau NR. Recent insights into HIV-1 Vif. Curr. Opin. Immunol 2004;16:477–482. [PubMed: 15245742]
- Ni HT, Hu S, Sheng WS, Olson JM, Cheeran MC, Chan AS, Lokensgard JR, Peterson PK. High-level expression of functional chemokine receptor CXCR4 on human neural precursor cells. Brain Res. Dev. Brain Res 2004;152:159–169.
- Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K. G to A hypermutation of hepatitis B virus. Hepatology 2005;41:626–633. [PubMed: 15726649]
- Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med 2006;203:41–46. [PubMed: 16418394]
- Rosler C, Kock J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsacker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005;42:301–309. [PubMed: 16025511]

- Rothwell NJ, Luheshi G, Toulmond S. Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacol. Ther 1996;69:85–95. [PubMed: 8984509]
- Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002;418:646–650. [PubMed: 12167863]
- Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y, Endo Y, Yamauchi J, Matsumoto T, Takaori-Kondo A, Ikai I, Chiba T. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem. Biophys. Res. Commun 2006;341:314–319. [PubMed: 16426578]
- Turelli P, Trono D. Editing at the crossroad of innate and adaptive immunity. Science 2005;307:1061– 1065. [PubMed: 15718460]
- Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. U. S. A 2000;97:14720–14725. [PubMed: 11121071]
- Wang X, Douglas SD, Metzger DS, Guo CJ, Li Y, O'Brien CP, Song L, Davis-Vogal A, Ho WZ. Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin. Exp. Res 2002;26:1880–1886. [PubMed: 12500113]
- Wang X, Douglas SD, Peng JS, Metzger DS, O'Brien CP, Zhang T, Ho WZ. Naltrexone inhibits alcoholmediated enhancement of HIV infection of T lymphocytes. J. Leukoc. Biol 2006;79:1166–1172. [PubMed: 16574767]
- Younkin DP, Tang CM, Hardy M, Reddy UR, Shi QY, Pleasure SJ, Lee VM, Pleasure D. Inducible expression of neuronal glutamate receptor channels in the NT2 human cell line. Proc. Natl. Acad. Sci. U. S. A 1993;90:2174–2178. [PubMed: 7681588]
- Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003;424:94–98. [PubMed: 12808465]

Wang et al. Page 11

Fig. 1.

APOBEC3G expression in the human immune cells, brain tissues and CNS cells. (A) RT-PCR analysis of APOBEC3G mRNA expression. Total cellular RNA extracted from the indicated cells was subjected to the real time RT-PCR using the specific primer pairs for APOBEC3G (70 bp) and GAPDH (127 bp). The amplified (35 cycles) products were then subjected to electrophoresis on 3% ultra pure agarose gel; (B) Western blot analysis of APOBEC3G protein expression. Proteins extracted from NT2-N cells, human peripheral blood lymphocytes (PBL) and primary human neurons (neural precursor cell-derived human neuronal cells) were subjected to Western blot assay using rabbit antibodies against APOPEC3G and actin. One representative of 3 independent experiments with similar results is shown.

Wang et al. Page 12

Fig. 2.

APOBEC3G expression in undifferentiated NT2 and differentiated NT2-N cells. (A) Real time RT-PCR analysis of expression of APOBEC3G mRNA. Total cellular RNA was extracted from NT2 and NT2-N cells (5-week retinoic acid [RA] -treated NT2 cells), and subjected to the real time RT-PCR using the specific primer pairs for APOBEC3G. The data is expressed as mean±SD of three independent experiments. (B) Western blot analysis of APOBEC3G protein expression. Equal amount of proteins extracted from undifferentiated NT2 cells and NT2-N cells was subjected to Western blot assay using rabbit antibodies against APOPEC3G and actin. The panels show the signal intensities (densitometry scanning units, DSUs) of protein

bands of the Western blot. One representative of 3 independent experiments with similar data is shown.

Wang et al. Page 14

Fig. 3.

Effect of IFN-α and IFN-β on APOBEC3G expression in NT2-N cells and U87-MG cells. (A) Time-course effect of IFN-α and IFN-β on APOBEC3G mRNA expression. The NT2-N cells were treated with IFN-α or IFN-β for the indicated time points. (B) Dose-dependent effect of IFN-α and IFN-β on APOBEC3G expression. The NT2-N cells were treated with IFN-α or IFN-β at indicated concentrations for 8 h. (C) Time-course effect of IFN-α and IFN-β on APOBEC3G mRNA expression. The U87-MG cells were treated with IFN-α or IFN-β for the indicated time points. (D) Dose-dependent effect of IFN-α and IFN-β on APOBEC3G expression. The U87-MG were treated with IFN- α or IFN-β at indicated concentrations for 8 h. For the data shown in A, B, C and D, APOBEC3G mRNA levels were analyzed by the realtime RT-PCR and were expressed as fold increase over untreated NT2-N cells or U87-MG cells (defined as 1). The data shown in A, B, C, and D is expressed as mean±SD of triplicate cultures, representative of three independent experiments (*, *p*<0.01; **, *p*<0.001; treated by IFN-α or IFN-β vs. untreated).

Wang et al. Page 15

Fig. 4.

Effects of cytokines on APOBEC3G expression in NT2-N cells. NT2-N cells were treated with IFN-γ (A), TNF-α (B), IL-1β (C), IL-4 (D), IL-6 (E) and TGF-β1 (F) at the indicated concentrations for 8 h. Total cellular RNA was subjected to the real-time RT-PCR for APOBEC3G mRNA, which is expressed as fold increase over untreated NT2-N cells (defined as 1). The data is expressed as mean±SD of triplicate cultures, representative of three independent experiments (*, *p*<0.01; **, *p*<0.001; treated by indicated cytokines vs. untreated). Wang et al. Page 16

LPS-Stimulated Macrophage SN % (v/v)

Fig. 5.

Effect of supernatants from LPS-stimulated macrophage cultures on APOBEC3G expression in NT2-N cells. (A) NT2-N cells were incubated in media conditioned with supernatants from unstimulated macrophage cultures and/or LPS or supernatants from LPS-stimulated macrophage cultures as indicated; (B) Dose-dependent effect of supernatants from LPSstimulated macrophage cultures on APOBEC3G expression. Total cellular RNA was subjected to the real-time RT-PCR for APOBEC3G mRNA, which is expressed as fold increase over untreated NT2-N cells (defined as 1). The data is expressed as mean±SD of triplicate cultures, representative of three independent experiments $(*, p<0.01; **, p<0.001$; treated by LPSstimulated macrophage SN vs. untreated).

Wang et al. Page 17

Time Post Infection (Hours)

Fig. 6.

Effect of the pseudotyped HIV-1 infection on APOBEC3G expression in NT2-N and U87-MG cells. NT2-N and U87-MG cells were infected with pseudotyped HIV-1. The cells were collected at indicated time points post-infection for analyzing APOBEC3G mRNA by the realtime RT-PCR. The result shown is the mean±SD of mRNA levels activity in triplicate cultures, which is expressed as fold increase over 0 hour cultures (defined as 1, **p*<0.01).

Wang et al. Page 18

Fig. 7.

Effect of APOBEC3G-specific siRNA on APOBEC3G expression and MLV-envpsedoutyped-HIV-1 replication in NT2-N and U87-MG cells. (A) Down-regulation of APOBEC3G mRNA expression in NT2-N and U87-MG cells by the siRNA against APOBEC3G. NT2-N and U87-MG cells were transfected with APOBEC3G-specific siRNA or siRNA-Ctl for 24 h. Total RNA was extracted for analyzing APOBEC3G mRNA expression by the real-time RT-PCR. (B) Effect of APOBEC3G-specific siRNA on MLV-envpsedoutyped-HIV-1 replication in NT2-N and U87-MG cells. The cells were transfected with the siRNAs as described above and then infected with MLV-env-psedoutype-HIV-1. NT2-N or U87-MG cells were collected for luciferase activity 72 h postinfection. The data shown in both A and B is expressed as mean±SD of triplicate cultures, representative of three independent experiments (*, *p*<0.05; siRNA-A3G treated vs. siRNA-Ctl treated).